Latest news with #CompassTherapeutics
Yahoo
11 hours ago
- Business
- Yahoo
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Call Details: Date: Monday, August 11, 2025 Time: 8:00 AM ET Webcast: Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Conference ID) Virtual/Replay availability: A replay will be archived for 90 days on Compass' Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at Investor Contactir@ ContactAnna Gifford, Chief of Staffmedia@ lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
25-07-2025
- Business
- Yahoo
Stifel Keeps Buy Rating on Compass Therapeutics (CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Performing Penny Stocks So Far in 2025. On July 14, Stifel reiterated its 'Buy' rating for Compass Therapeutics, Inc. (NASDAQ:CMPX) with a price target of $11. This decision came after investor meetings with the company's management. According to the research firm, the extended timeline for overall survival event accrual in the Phase 2/3 COMPANION-002 trial is a good thing. The trial is testing paclitaxel with or without tovecimig in patients with second-line biliary tract cancer. A biopharmacist holding a magnifying glass up against a microscope lens, studying a biological sample. Compass Therapeutics, Inc. (NASDAQ:CMPX) now expects to share the topline data in the fourth quarter of 2025. This means patients will be followed up for more than 19 months on average. Stifel noted that this is important because in this disease, the overall survival of the control arm rarely goes beyond 6 months. Besides the COMPANION-002 trial, Stiefl analysts believe upcoming data disclosures for two other compounds in the second half of 2025 could potentially prove to be important catalysts for Compass Therapeutics, Inc. (NASDAQ:CMPX). These include Phase 1 dose-escalation data for CTX-8371, a PD-1xPD-L1 bispecific antibody, and preclinical data for CTX-10726, a PD-1xVEGF-A bispecific antibody. Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. The company focuses on the relationship between angiogenesis, the immune system, and tumor growth. While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-07-2025
- Business
- Yahoo
Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top high-return penny stocks to buy now. On July 14, Stifel reiterated its Buy rating and $11.00 price target for CMPX. The firm views the extended timeline for topline data from the Phase 2/3 COMPANION-002 trial—now expected in Q4 2025—as a positive, given the 19-month follow-up in a cancer type with typically short survival rates. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. Beyond COMPANION-002, Stifel highlighted two upcoming 2025 catalysts: Phase 1 results for CTX-8371, a PD-1xPD-L1 bispecific antibody, and preclinical data on CTX-10726 targeting PD-1 and VEGF-A. Interest is also growing around CTX-837's unique multi-modal mechanism, reinforcing Compass's innovation in immuno-oncology. Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biotech company developing antibody-based cancer treatments in the U.S. Its lead candidates include bispecific antibodies like tovecimig (targeting DLL4 and VEGF-A), CTX-471 (stimulating CD137 for immune activation), and CTX-8371 (blocking PD-1/PD-L1). The company also advances CTX-10726 and VEGF-focused bispecifics aimed at enhancing anti-tumor immunity and inhibiting angiogenesis. While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
15-07-2025
- Business
- Business Insider
Compass Therapeutics (CMPX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on Compass Therapeutics today and set a price target of $11.00. The company's shares opened today at $2.66. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Willey covers the Healthcare sector, focusing on stocks such as Incyte, Bicara Therapeutics Inc., and Exelixis. According to TipRanks, Willey has an average return of 2.0% and a 40.34% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compass Therapeutics with a $13.20 average price target, which is a 396.24% upside from current levels. In a report released on July 1, Raymond James also initiated coverage with a Buy rating on the stock with a $9.00 price target. CMPX market cap is currently $373.4M and has a P/E ratio of -6.74. Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMPX in relation to earlier this year. Most recently, in May 2025, Thomas Schuetz, the CEO of CMPX bought 10,000.00 shares for a total of $21,100.00.
Yahoo
14-05-2025
- Business
- Yahoo
Spotlight On Three Promising Penny Stocks In May 2025
As the U.S. market rallies with tech stocks leading gains, investors are increasingly optimistic about the potential for continued growth. Penny stocks, a term that may seem outdated, still represent an intriguing investment area for those interested in smaller or newer companies. By focusing on penny stocks with strong financial health and clear growth potential, investors can uncover opportunities that offer both stability and upside. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.61 $372.2M ★★★★☆☆ IDenta (OTCPK:IDTA) $0.75 $3.03M ★★★★★★ Tuya (NYSE:TUYA) $2.71 $1.54B ★★★★★★ WM Technology (NasdaqGS:MAPS) $1.14 $188.36M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $4.44 $56.66M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.66 $91.2M ★★★★★★ BAB (OTCPK:BABB) $0.84 $5.96M ★★★★★★ Dingdong (Cayman) (NYSE:DDL) $2.37 $518.62M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.315 $81.59M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.935 $81.31M ★★★★★☆ Click here to see the full list of 756 stocks from our US Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics for treating various human diseases, with a market cap of $277.95 million. Operations: Compass Therapeutics, Inc. currently does not report any revenue segments. Market Cap: $277.95M Compass Therapeutics, Inc., with a market cap of US$277.95 million, is a pre-revenue biopharmaceutical company focused on antibody-based therapeutics. Despite its unprofitability and negative return on equity of -50.07%, the company maintains a strong balance sheet with short-term assets exceeding liabilities and no debt. Recent developments include promising clinical trial results for tovecimig in biliary tract cancer (BTC), showing significant improvement in overall response rate when combined with paclitaxel compared to paclitaxel alone. However, high volatility remains a concern, as does the relatively inexperienced management team with an average tenure of 1.8 years. Click here and access our complete financial health analysis report to understand the dynamics of Compass Therapeutics. Assess Compass Therapeutics' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Village Farms International, Inc. operates in North America producing, marketing, and distributing greenhouse-grown tomatoes, bell peppers, cucumbers, and mini-cukes with a market cap of $78.98 million. Operations: Village Farms International does not report specific revenue segments. Market Cap: $78.98M Village Farms International, with a market cap of US$78.98 million, operates in the greenhouse-grown produce sector and is currently unprofitable with increasing losses over five years. Despite this, the company has reduced its debt-to-equity ratio and maintains a satisfactory net debt level. Recent refinancing efforts have improved financial covenants on its cannabis credit facility, extending maturity to 2028. The company faces delisting risks from Nasdaq due to non-compliance with bid price requirements but has received an extension until October 2025 to rectify this issue. Revenue growth is expected at 13.62% annually, though profitability remains elusive in the near term. Dive into the specifics of Village Farms International here with our thorough balance sheet health report. Examine Village Farms International's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★★ Overview: RPC, Inc. provides a variety of oilfield services and equipment to oil and gas companies engaged in exploration, production, and development activities, with a market cap of approximately $1.08 billion. Operations: RPC's revenue is primarily derived from its Technical Services segment, which accounts for $1.28 billion, complemented by its Support Services segment contributing $88.59 million. Market Cap: $1.08B RPC, Inc., with a market cap of US$1.08 billion, operates in the oilfield services sector and has shown profitability growth over the past five years. Despite recent challenges, including a decline in sales to US$332.88 million for Q1 2025 from US$377.83 million a year ago, RPC maintains no debt and strong short-term assets exceeding liabilities. The company is exploring acquisitions to leverage its robust balance sheet and liquidity amidst industry volatility. Although its profit margins have decreased, RPC's price-to-earnings ratio suggests it may be undervalued compared to the broader U.S. market average of 17.9x. Take a closer look at RPC's potential here in our financial health report. Gain insights into RPC's future direction by reviewing our growth report. Click through to start exploring the rest of the 753 US Penny Stocks now. Contemplating Other Strategies? The latest GPUs need a type of rare earth metal called Terbium and there are only 23 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:CMPX NasdaqCM:VFF and NYSE:RES. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
